Spots Global Cancer Trial Database for non small cell lung cancer (nsclc)
Every month we try and update this database with for non small cell lung cancer (nsclc) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC | NCT00492206 | Non Small Cell ... | Cetuximab | 18 Years - | University of Pittsburgh | |
| Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases | NCT02132598 | Non Small Cell ... Metastases to t... | cabozantinib | 18 Years - | University of Pittsburgh | |
| A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases | NCT03497767 | Metastatic Non ... | Osimertinib Stereotactic Ra... | 18 Years - | Trans Tasman Radiation Oncology Group | |
| Study of PX-866 and Docetaxel in Solid Tumors | NCT01204099 | Non Small Cell ... Squamous Cell C... | Docetaxel PX-866 | 18 Years - | Seagen Inc. | |
| Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | NCT02988817 | Ovarian Cancer Cervical Cancer Endometrial Can... Non Small Cell ... Thyroid Cancer Melanoma Sarcoma Solid Tumors | Enapotamab vedo... | 18 Years - | Genmab | |
| Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors. | NCT03447678 | Non Small Cell ... | Pembrolizumab | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies | NCT04772989 | Advanced Solid ... Non Small Cell ... Melanoma Cervical Cancer Multiple Myelom... Lymphoma, Non-H... Diffuse Large B... Gastric Cancer Gastroesophagea... Esophageal Canc... | AB308 Zimberelimab | 18 Years - | Arcus Biosciences, Inc. | |
| Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010) | NCT01905657 | Non Small Cell ... | Pembrolizumab Docetaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | NCT06026410 | Solid Tumors Wi... Non Small Cell ... Colorectal Canc... Pancreatic Duct... Clear Cell Rena... | KO-2806 Cabozantinib Adagrasib | 18 Years - | Kura Oncology, Inc. | |
| Complete Endosonographic Intrathoracic Nodal Staging of Lung Cancer Patients in Whom SABR is Considered | NCT02997449 | Non Small Cell ... Intrathoracic N... | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | ||
| Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004 | NCT00285675 | Androgen Indepe... Non Small Cell ... | DN-101 (calcitr... | 18 Years - | Novacea | |
| Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers | NCT01005797 | Renal Cancer Non Small Cell ... Soft Tissue Sar... | Panobinostat (L... | 18 Years - | Medical University of South Carolina | |
| GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors | NCT04083599 | Malignant Solid... Non Small Cell ... Colorectal Canc... Melanoma Head and Neck S... Pancreatic Duct... | GEN1042 Pembrolizumab Cisplatin Carboplatin 5-FU Gemcitabine Nab paclitaxel Pemetrexed Paclitaxel | 18 Years - | Genmab | |
| Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM | NCT02555007 | Non Small Cell ... Malignant Pleur... | Vinorelbine | 18 Years - | Assistance Publique Hopitaux De Marseille | |
| Immunization of Patients With Non Small Cell Lung Cancer (NSCLC) | NCT00793208 | Non Small Cell ... | semi-allogeneic... | 18 Years - | University of Pittsburgh | |
| A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase | NCT00528281 | Lung Cancer, No... | Lapatinib Pemetrexed | 18 Years - | GlaxoSmithKline | |
| A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers | NCT04272203 | Acute Myeloid L... Non Small Cell ... Cancer | ABBV-184 | 18 Years - | AbbVie | |
| Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC | NCT01282437 | Non Small Cell ... Radical Treatme... Stage III Non-S... | Prophylactic Cr... | 18 Years - | Maastricht Radiation Oncology | |
| Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors | NCT04721015 | Advanced Solid ... Non Small Cell ... | ABBV-637 Docetaxel Osimertinib | 18 Years - | AbbVie | |
| Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers | NCT02639026 | Metastatic Melanoma Non Small Cell ... Breast Cancer Pancreatic Canc... | Radiotherapy MEDI4736 Tremelimumab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen | NCT02066636 | Non Small Cell ... | Nivolumab | 18 Years - | Bristol-Myers Squibb | |
| A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen | NCT02066636 | Non Small Cell ... | Nivolumab | 18 Years - | Bristol-Myers Squibb | |
| A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases | NCT03497767 | Metastatic Non ... | Osimertinib Stereotactic Ra... | 18 Years - | Trans Tasman Radiation Oncology Group | |
| Tarceva Italian Lung Optimization tRial | NCT00637910 | Non Small Cell ... | Erlotinib Docetaxel | 18 Years - | Fatebenefratelli and Ophthalmic Hospital | |
| Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT | NCT02456246 | Non Small Cell ... | FLT-PET | 18 Years - | University Health Network, Toronto | |
| Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers | NCT01005797 | Renal Cancer Non Small Cell ... Soft Tissue Sar... | Panobinostat (L... | 18 Years - | Medical University of South Carolina | |
| Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004 | NCT00285675 | Androgen Indepe... Non Small Cell ... | DN-101 (calcitr... | 18 Years - | Novacea | |
| Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment | NCT00683306 | Non Small Cell ... | ZD1839 (Iressa) | 18 Years - 130 Years | AstraZeneca | |
| AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients | NCT00890825 | Non Small Cell ... | AZD6244 docetaxel Placebo | 18 Years - 130 Years | AstraZeneca | |
| GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors | NCT04083599 | Malignant Solid... Non Small Cell ... Colorectal Canc... Melanoma Head and Neck S... Pancreatic Duct... | GEN1042 Pembrolizumab Cisplatin Carboplatin 5-FU Gemcitabine Nab paclitaxel Pemetrexed Paclitaxel | 18 Years - | Genmab | |
| Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010) | NCT01905657 | Non Small Cell ... | Pembrolizumab Docetaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Nitroglycerin in Non-small Cell Lung Cancer | NCT01210378 | Non Small Cell ... | Nitroglycerin p... | 18 Years - | Maastricht Radiation Oncology | |
| Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers | NCT02639026 | Metastatic Melanoma Non Small Cell ... Breast Cancer Pancreatic Canc... | Radiotherapy MEDI4736 Tremelimumab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT | NCT02456246 | Non Small Cell ... | FLT-PET | 18 Years - | University Health Network, Toronto | |
| Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial | NCT02176369 | Non-small Cell ... Non-small Cell ... | Vinorelbine | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects | NCT01323062 | Non Small Cell ... | Bavituximab | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression | NCT04274907 | Non Small Cell ... Cancer | Venetoclax Pembrolizumab | 18 Years - | AbbVie | |
| Single Arm on the Tolerability of Weekly Nab-paclitaxel | NCT01702844 | Non Small Cell ... | Nab-Paclitaxel | 70 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies | NCT05473156 | Locally Advance... Non Small Cell ... Head and Neck S... Esophageal Squa... | AP203 AP203 | 18 Years - | AP Biosciences Inc. | |
| Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases | NCT02132598 | Non Small Cell ... Metastases to t... | cabozantinib | 18 Years - | University of Pittsburgh | |
| Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO | NCT01465802 | Non Small Cell ... | Dacomitinib Dacomitinib Doxycycline Probiotic Alclometasone c... | 18 Years - | Pfizer | |
| Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment | NCT00683306 | Non Small Cell ... | ZD1839 (Iressa) | 18 Years - 130 Years | AstraZeneca | |
| Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects | NCT01323062 | Non Small Cell ... | Bavituximab | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Complete Endosonographic Intrathoracic Nodal Staging of Lung Cancer Patients in Whom SABR is Considered | NCT02997449 | Non Small Cell ... Intrathoracic N... | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | ||
| A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies | NCT04772989 | Advanced Solid ... Non Small Cell ... Melanoma Cervical Cancer Multiple Myelom... Lymphoma, Non-H... Diffuse Large B... Gastric Cancer Gastroesophagea... Esophageal Canc... | AB308 Zimberelimab | 18 Years - | Arcus Biosciences, Inc. | |
| A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies | NCT04772989 | Advanced Solid ... Non Small Cell ... Melanoma Cervical Cancer Multiple Myelom... Lymphoma, Non-H... Diffuse Large B... Gastric Cancer Gastroesophagea... Esophageal Canc... | AB308 Zimberelimab | 18 Years - | Arcus Biosciences, Inc. | |
| Study of PX-866 and Docetaxel in Solid Tumors | NCT01204099 | Non Small Cell ... Squamous Cell C... | Docetaxel PX-866 | 18 Years - | Seagen Inc. | |
| Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC | NCT01282437 | Non Small Cell ... Radical Treatme... Stage III Non-S... | Prophylactic Cr... | 18 Years - | Maastricht Radiation Oncology | |
| Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT | NCT02456246 | Non Small Cell ... | FLT-PET | 18 Years - | University Health Network, Toronto | |
| A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase | NCT00528281 | Lung Cancer, No... | Lapatinib Pemetrexed | 18 Years - | GlaxoSmithKline | |
| Osimertinib Study in Indian Patients | NCT03853551 | Non Small Cell ... | Osimertinib | 18 Years - 99 Years | AstraZeneca | |
| Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer | NCT00564876 | Carcinoma, Non-... | Dasatinib | 18 Years - | Duke University | |
| Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer | NCT01594398 | Lung Cancer Non Small Cell ... Breast Cancer Estrogen Recept... | entinostat entinostat Erlotinib Erlotinib Exemestane Exemestane | 18 Years - 90 Years | Syndax Pharmaceuticals | |
| Single Arm on the Tolerability of Weekly Nab-paclitaxel | NCT01702844 | Non Small Cell ... | Nab-Paclitaxel | 70 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) | NCT00527735 | Lung Cancer Small Cell Lung... Carcinoma, Non-... | Ipilimumab Placebo Paclitaxel Carboplatin | 18 Years - | Bristol-Myers Squibb | |
| Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer | NCT01498562 | Non Small Cell ... | Gefitinib and N... Gefitinib | 20 Years - | Yonsei University | |
| Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004 | NCT00285675 | Androgen Indepe... Non Small Cell ... | DN-101 (calcitr... | 18 Years - | Novacea | |
| Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) | NCT00527735 | Lung Cancer Small Cell Lung... Carcinoma, Non-... | Ipilimumab Placebo Paclitaxel Carboplatin | 18 Years - | Bristol-Myers Squibb |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
